Roberta Mazzone, Visiting Student
Jan 2018 - Ongoing
Short Term Scientific Mission
Prof. Paul E. Brennan’s Group, Target Discovery Institute, University of Oxford, UK
Dissection of epigenetic mechanisms underlying the GAA-mediated FXN silencing in Friedreich's ataxia to identify FXN up-regulating compounds.
Nov 2015 – to date
PhD Student at “Sapienza” - University of Rome, Italy
Study emphasis: Medicinal and Organic Chemistry, Biochemistry, Pharmaceutical Technology and Pharmacology.
Supervisor: Prof. Antonello Mai
Thesis project: various projects including the design and synthesis of pyrrole-based EZH2 inhibitors, design and synthesis of novel AGPS inhibitors as well as design and synthesis of DHP-based SIRT activators and LSD1 inhibitors.
Pharmacists Qualifying examination at “Sapienza” University of Rome, Italy
May 2015- Oct 2015
Traineeship at Institute for Research in Biomedicine IRB, Barcelona
Title of project: Synthesis of somatostatin analogs with unnatural aminoacids. Specifically looking at the development of novel peptides structurally based on the somatostatin scaffold with an aim of elucidating the key aspects of the selectivity against the five somatostatin receptors. This was achieved by introducing unnatural aminoacids previously synthetized in the original sequence.
Oct 2009 - Jan 2015
Integrated Master’s degree in Medicinal Chemistry and Pharmaceutical Technology Sapienza - University of Rome, Italy
Thesis project: An in vitro investigation on the phase I and phase II metabolism of aminoalkylindoles. Selection of the most appropriate marker(s) of abuse.
Supervisor: Prof. Francesco Botrè
Final grade: First Class Honours - 110 e lode/110.
Title of the dissertation: Investigating the phase I metabolism of representative aminoalkyindoles by in vitro studies in order to design the most appropriate analytical strategy to detect their intake in doping control tests. The alterations caused by physiological and environmental factors were also considered.
1. Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors. Milelli A, Marchetti C., Turrini E., Catanzaro E., Mazzone R., Tomaselli D., Fimognari C., Tumiatti V., Minarini A. Bioorg Med Chem Lett. 2018, 28(6):1001-1004.
2. Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy. Mazzone R., Zwergel C., Mai A., and Valente S. Clin Epigenetics. 2017; 9:59.